Arena (ARNA) Clears Final BELVIQ Marketing Hurdle; Could Make U.S. Debut in June
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Arena (ARNA) Confirms BELVIQ Will Soon Be Available for Sale in the U.S.
May 7, 2013 3:36 PM EDTArena Pharmaceuticals, Inc. (NASDAQ: ARNA) confirmed the Office of the Federal Register filed for public inspection the US Drug Enforcement Administration's (DEA) final rule placing BELVIQ (pronounced BEL-VEEK) into Schedule IV of the Controlled Substances Act. The scheduling designation will be effective 30 days after tomorrow's expected publication in the Federal Register. Following the effective date, BELVIQ will be available to patients in the United States by prescription, and Arena will... More
VIVUS, Inc. (VVUS) Ticks Higher as Arena (ARNA) Pulls BELVIQ MAA in Europe
May 3, 2013 8:43 AM EDTVIVUS, Inc. (Nasdaq: VVUS) is indicated higher in early trading Friday following word that a key competitor will be less fierce in at least one market.
After markets closed on Thursday, Arena Pharmaceuticals (Nasdaq: ARNA)... More
